Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001171843-16-009093
Filing Date
2016-04-11
Accepted
2016-04-11 08:46:49
Documents
5
Effectiveness Date
2016-04-11

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS defa14a_041116.htm DEFA14A 12889
2 GRAPHIC proxycard_1.jpg GRAPHIC 120056
3 GRAPHIC proxycard_2.jpg GRAPHIC 194506
4 GRAPHIC proxycard_3.jpg GRAPHIC 91458
5 GRAPHIC proxycard_4.jpg GRAPHIC 38376
  Complete submission text file 0001171843-16-009093.txt   626434
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-23186 | Film No.: 161563953
SIC: 2836 Biological Products, (No Diagnostic Substances)